Clinical characteristics of patients with RA-OP treated with bDMARD.
| No. | Age/sex | RA Duration, Mos* | csDMARD | PSL | bDMARD | bDMARD Duration, Mos* | RF, IU/ml | DAS28-ESR | Comorbidity of Pulmonary Disease |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 53/F | 27 | MTX | + | IFX | 2 | 6 | 3.3 | — |
| 2 | 56/F | 35 | MTX | − | IFX | 12 | 45 | 4.3 | — |
| 3 | 60/F | 36 | MTX | − | ETN | 14 | 195 | 4.4 | — |
| 4 | 31/F | 28 | MTX | − | ETN | 1 | 45 | 2.1 | — |
| 5 | 66/F | 102 | MTX, TAC | + | TCZ | 15 | 112 | 2.1 | — |
| 6 | 66/M | 84 | MTX | − | IFX | 18 | 122 | 3.8 | — |
| 7 | 79/F | 144 | — | − | ETN | 1 | < 5 | 2.8 | ILD |
| 8 | 78/F | 8 | SASP | + | ETN | 0 | 307 | 5.1 | ILD |
| 9 | 42/F | 106 | MTX | + | IFX | 62 | < 3 | 3.4 | — |
| 10 | 41/F | 258 | LEF | + | ETN | 60 | 29 | 1.4 | — |
| 11 | 63/M | 84 | MTX, SASP | − | IFX | 26 | 86 | 3.0 | — |
| 12 | 56/M | 86 | MTX | − | IFX | 27 | 403 | 4.8 | — |
↵* RA disease durations and biological therapy durations were defined as periods at the development of OP. RA: rheumatoid arthritis; OP: organizing pneumonia; DMARD: disease-modifying antirheumatic drugs; bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; PSL: prednisolone; RF: rheumatoid factor; DAS28: Disease Activity Score at 28 joints; ESR: erythrocyte sedimentation rate; MTX: methotrexate; TAC: tacrolimus; SASP: salazosulfapyridine; LEF: leflunomide; IFX: infliximab; ETN: etanercept; TCZ: tocilizumab; ILD: interstitial lung disease.